Wuhan Keqian Biology Co Ltd

688526 · SHG · Healthcare / Biotechnology

11.47CNY+0.04 (+0.35%)

Price History

Full chart

Market Stats

Previous Close11.43

Open11.43

Day Range11.38 – 11.63

52-Week Range11.65 – 17.19

Volume1.28M

Market Cap5.75B

P/E (TTM)18.15

Forward P/E0.00

EPS0.68

Dividend Yield5.19%

Beta0.34

50-Day Avg12.73

200-Day Avg14.21

About

Wuhan Keqian Biology Co.,Ltd focuses on the research and development, production, sales, and animal epidemic prevention technical services of veterinary biological products in China. It offers vaccines for pigs, poultry, and pets, as well as diagnostic reagents. Wuhan Keqian Biology Co.,Ltd was founded in 2001 and is based in Wuhan, China.

Company Details

SectorHealthcare
IndustryBiotechnology
CEOMs. Mulin Chen
Employees935
HeadquartersNo. 419, Gaoxin 2nd Road, Wuhan, China, 430073, China
Websitehttps://www.kqbio.com

Leadership

Ms. Mulin ChenGM & Chairman · b. 1988
Mr. Ming ZhongCFO, Deputy GM & Vice Chairman · b. 1983
Mr. Gaoyuan XuExecutive Vice President of R&D & Director of Core Technical Personnel · b. 1976
Ms. Tiantian ZouBoard Secretary · b. 1983
Mr. Guanping ChenDeputy General Manager · b. 1967
Mr. Xibiao TangDeputy General Manager · b. 1980
Mr. Deng HongDeputy General Manager · b. 1984
Chan Cha ChenAccounting Supervisor

Financials

Income Statement

Currency: CNY	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	390.40M	632.83M	735.30M	507.51M	843.23M	1.10B	1.00B	1.06B	941.92M	950.29M
Growth (%)	-	+62.10%	+16.19%	-30.98%	+66.15%	+30.81%	-9.22%	+6.27%	-11.48%	+0.89%
Cost of Revenue	82.95M	103.39M	122.97M	109.95M	151.17M	230.42M	279.05M	321.43M	360.45M	313.67M
Gross Profit	307.45M	529.44M	612.33M	397.56M	692.06M	872.60M	722.22M	742.65M	581.48M	950.29M
Gross Margin	78.75%	83.66%	83.28%	78.34%	82.07%	79.11%	72.13%	69.79%	61.73%	100.00%
Operating Expense	97.51M	152.90M	160.43M	118.51M	167.75M	211.60M	255.50M	283.52M	142.63M	471.88M
Operating Income	209.94M	376.55M	451.90M	279.05M	524.31M	661.00M	466.71M	459.13M	438.85M	478.42M
Operating Margin	53.78%	59.50%	61.46%	54.98%	62.18%	59.93%	46.61%	43.15%	46.59%	50.34%
EBITDA	221.56M	399.77M	486.49M	315.50M	557.46M	724.50M	569.00M	578.98M	551.13M	585.07M
EBITDA Margin	56.75%	63.17%	66.16%	62.17%	66.11%	65.68%	56.83%	54.41%	58.51%	61.57%
Net Income	186.16M	320.32M	388.97M	242.64M	447.80M	570.74M	409.52M	395.93M	382.35M	415.60M
Net Income Margin	47.68%	50.62%	52.90%	47.81%	53.11%	51.74%	40.90%	37.21%	40.59%	43.73%
R&D	21.55M	53.16M	48.18M	47.37M	59.08M	80.00M	102.75M	88.51M	88.43M	96.41M
R&D as % of Total Revenue	5.52%	8.40%	6.55%	9.33%	7.01%	7.25%	10.26%	8.32%	9.39%	10.15%
Interest Expense	24.38K	29.61K	27.79K	46.51K	771.97K	1.81M	5.45M	8.16M	4.77M	1.77M
Interest Expense % of Total Revenue	0.01%	0.00%	0.00%	0.01%	0.09%	0.16%	0.54%	0.77%	0.51%	0.19%

Balance Sheet

Currency: CNY	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	592.11M	932.27M	1.23B	1.37B	3.11B	3.73B	4.39B	4.67B	4.50B	4.79B
Total Liabilities	179.01M	258.86M	353.51M	252.48M	402.40M	571.41M	891.63M	833.59M	552.80M	-4.17B
Total Equity	412.77M	673.08M	876.34M	1.12B	2.71B	3.15B	3.50B	3.84B	3.94B	4.17B
Cash	268.34M	59.04M	610.64M	671.04M	1.91B	555.36M	456.07M	581.74M	543.48M	176.80M
Total Debt	-	2.55M	-	-	60.06M	78.09M	279.48M	293.51M	5.55M	-
Net Debt	-268.34M	-56.49M	-610.64M	-671.04M	-1.85B	-477.27M	-176.59M	-288.23M	-537.93M	-

Cash Flow

Currency: CNY	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	220.69M	337.61M	351.83M	154.89M	400.14M	531.27M	423.71M	538.03M	392.68M	468.54M
Investing Cash Flow	2.79M	-499.66M	323.03M	-623.72M	-1.19B	-331.10M	-637.13M	-329.00M	96.59M	-
Financing Cash Flow	-34.03M	-49.80M	-120.72M	-85.75M	1.21B	-121.18M	113.52M	-102.43M	-503.18M	-
Capital Expenditure	29.13M	129.11M	31.42M	137.74M	111.60M	374.45M	102.85M	104.50M	106.94M	123.88M
Free Cash Flow	191.56M	208.50M	320.41M	17.15M	288.54M	156.82M	320.86M	433.53M	285.74M	344.66M
Dividends Paid	30.02M	47.25M	122.28M	85.75M	368.96K	134.85M	88.38M	97.09M	204.58M	199.48M
FCF to OCF	86.80%	61.76%	91.07%	11.07%	72.11%	29.52%	75.73%	80.58%	72.77%	73.56%
Dividend Paid to FCF	15.67%	22.66%	38.16%	499.93%	0.13%	85.99%	27.54%	22.39%	71.60%	57.88%

Earnings

Report Date	Oct 29, 2020	Feb 25, 2021	Apr 26, 2021	Aug 26, 2021	Oct 27, 2021	Apr 18, 2022	Aug 29, 2022	Oct 28, 2022	Apr 17, 2023
EPS Estimate	-	-	-	-	-	-	-	-	-
EPS Actual	0.29	0.28	0.36	0.25	0.21	0.20	0.14	0.27	0.27
Surprise	-	-	-	-	-	-	-	-	-
Timing	Pre-market	After-hours	Pre-market	After-hours	Pre-market	After-hours	Pre-market	After-hours	Pre-market

Key Statistics & Ratios

Market Cap5.75B

Enterprise Value3.92B

Trailing P/E18.15

Forward P/E0.00

Price / Sales6.88

Price / Book1.43

EPS0.68

Book Value8.77

Revenue (TTM)836.28M

Gross Profit (TTM)506.73M

EBITDA363.87M

Profit Margin37.61%

Operating Margin-1.00%

Return on Equity7.73%

Return on Assets3.38%

Shares Outstanding466.13M

Shares Float111.28M

Beta0.34

Dividend Yield5.19%

Dividend Rate0.64

Payout Ratio94.12%

Dividends

20261×

0.64May 26, 2026

20251×

0.43Jun 16, 2025

20241×

0.43May 22, 2024

20231×

0.19Jun 6, 2023

20221×

0.19May 31, 2022

20211×

0.29Jun 23, 2021